HK1082919A1 - Transdermal treatment of postmenopausal women using ultra-low doses of estrogen - Google Patents

Transdermal treatment of postmenopausal women using ultra-low doses of estrogen

Info

Publication number
HK1082919A1
HK1082919A1 HK06102902A HK06102902A HK1082919A1 HK 1082919 A1 HK1082919 A1 HK 1082919A1 HK 06102902 A HK06102902 A HK 06102902A HK 06102902 A HK06102902 A HK 06102902A HK 1082919 A1 HK1082919 A1 HK 1082919A1
Authority
HK
Hong Kong
Prior art keywords
estrogen
ultra
low doses
postmenopausal women
transdermal treatment
Prior art date
Application number
HK06102902A
Other languages
English (en)
Inventor
Cummings Steven
Ellman Herman
Ettinger Bruce
Original Assignee
Univ California
Kaiser Foundation Health Plan
Permanente Medical Group Inc
Berlex Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25523181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1082919(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ California, Kaiser Foundation Health Plan, Permanente Medical Group Inc, Berlex Lab filed Critical Univ California
Publication of HK1082919A1 publication Critical patent/HK1082919A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
HK06102902A 1997-11-21 2006-03-06 Transdermal treatment of postmenopausal women using ultra-low doses of estrogen HK1082919A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/975,599 US5891868A (en) 1997-11-21 1997-11-21 Methods for treating postmenopausal women using ultra-low doses of estrogen

Publications (1)

Publication Number Publication Date
HK1082919A1 true HK1082919A1 (en) 2006-06-23

Family

ID=25523181

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06102902A HK1082919A1 (en) 1997-11-21 2006-03-06 Transdermal treatment of postmenopausal women using ultra-low doses of estrogen

Country Status (26)

Country Link
US (1) US5891868A (tr)
EP (2) EP1570848B1 (tr)
JP (2) JP2001523722A (tr)
KR (1) KR100576568B1 (tr)
CN (1) CN100398110C (tr)
AT (2) ATE291430T1 (tr)
AU (1) AU760108B2 (tr)
BR (1) BR9814984A (tr)
CA (1) CA2306881C (tr)
CL (1) CL2004001852A1 (tr)
CZ (1) CZ299226B6 (tr)
DE (2) DE69839026T2 (tr)
EA (1) EA004573B1 (tr)
EE (1) EE04221B1 (tr)
ES (2) ES2241188T3 (tr)
HK (1) HK1082919A1 (tr)
HU (1) HUP0004339A3 (tr)
IL (1) IL136175A (tr)
IS (1) IS2132B (tr)
NO (1) NO326929B1 (tr)
NZ (1) NZ504668A (tr)
PL (1) PL193897B1 (tr)
PT (1) PT1032398E (tr)
SK (1) SK284971B6 (tr)
TR (1) TR200001460T2 (tr)
WO (1) WO1999026631A1 (tr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407082B1 (en) * 1996-09-13 2002-06-18 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a vitamin D compound
US6765002B2 (en) 2000-03-21 2004-07-20 Gustavo Rodriguez Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium
US6028064A (en) 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
US6034074A (en) 1996-09-13 2000-03-07 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a Vitamin D compound
US6511970B1 (en) 1996-09-13 2003-01-28 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
US6692763B1 (en) * 1998-11-19 2004-02-17 The Regents Of The University Of California Methods for treating postmenopausal women using ultra-low doses of estrogen
US5891868A (en) * 1997-11-21 1999-04-06 Kaiser Foundation Health Plan, Inc. Methods for treating postmenopausal women using ultra-low doses of estrogen
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
HUP0300887A2 (hu) * 2000-01-14 2003-07-28 Schering Aktiengesellschaft Szteroid szerkezeteket tartalmazó gyógyszerkészítmények és alkalmazásuk
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
US20040176336A1 (en) * 2000-03-21 2004-09-09 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US20010044431A1 (en) * 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US20050113351A1 (en) * 2000-03-21 2005-05-26 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
EP1334367B1 (en) * 2000-10-13 2006-06-07 Abbott Laboratories A method of determining the initial dose of vitamin d compounds
PL367094A1 (en) 2001-07-31 2005-02-21 Pfizer Products Inc. Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins
JP2007512225A (ja) * 2003-07-31 2007-05-17 アイバックス コーポレイション 脳標的ステロイド薬剤供給系用の経粘膜剤形
US7685012B2 (en) * 2003-12-30 2010-03-23 Wilson Thomas W Method and system for analyzing resource allocation based on cohort times
US20060040904A1 (en) * 2004-08-17 2006-02-23 Ahmed Salah U Vaginal cream compositions, kits thereof and methods of using thereof
US8022053B2 (en) * 2004-11-02 2011-09-20 Bayer Schering Pharma Aktiengesellschaft Oral solid dosage forms containing a low dose of estradiol
WO2006084082A1 (en) * 2005-02-03 2006-08-10 Duramed Pharmaceuticals, Inc. Compositions of unconjugated estrogens and methods for their use
US8834862B2 (en) * 2005-04-19 2014-09-16 Nanocyte Inc. Methods, compositions and devices utilizing stinging cells/capsules for conditioning a tissue prior to delivery of an active agent
EP2289486A1 (en) * 2005-12-27 2011-03-02 Teva Women's Health, Inc. Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof
US20070254036A1 (en) * 2006-04-13 2007-11-01 Besins Healthcare Sa Treatment of menopause associated symptoms
CN101902996B (zh) * 2007-10-15 2014-11-26 阿尔扎公司 芬太尼的一天更换一次透皮施用
US20090110656A1 (en) * 2007-10-31 2009-04-30 Lemke Sarah A Skin cooling composition
US20090157153A1 (en) * 2007-12-13 2009-06-18 Sarah Anne Lemke Skin cooling system
DE102009007771B4 (de) 2009-02-05 2012-02-16 Bayer Schering Pharma Aktiengesellschaft Bukkales Applikationssystem, 17α-Estradiol enthaltend
US20130140210A1 (en) * 2010-04-15 2013-06-06 Bayer Intellectual Property Gmbh Low-dosed solid oral dosage forms for hrt
HUP1000335A2 (en) * 2010-06-22 2012-02-28 Avidin Kft Use of an estrogen derivative for the treatment and/or prevention of psychiatric conditions
RU2456955C1 (ru) * 2011-03-01 2012-07-27 Государственное образовательное учреждение высшего профессионального образования "Алтайский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" Способ ортопедического лечения женщин постменопаузального периода съемными пластиночными протезами
CN102397550B (zh) * 2011-08-30 2013-05-08 广东医学院 一组由阿司匹林与雌激素组成的防治骨质疏松症的药物组合物
JP2013097693A (ja) * 2011-11-04 2013-05-20 Hitachi Solutions Ltd 骨粗鬆症リスク判定システム及びプログラム
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
KR101881791B1 (ko) * 2013-10-07 2018-07-25 테이코쿠 팔마 유에스에이, 인코포레이티드 비진정성 덱스메데토미딘 경피 조성물을 사용하여 금단 증후군을 치료하기 위한 방법 및 조성물
JP2017516768A (ja) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然の併用ホルモン補充療法剤及び療法
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
EP3435977A4 (en) 2016-04-01 2019-10-16 Therapeuticsmd, Inc. PHARMACEUTICAL COMPOSITION OF STEROID HORMONE
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US4031894A (en) * 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
US4722941A (en) * 1978-06-07 1988-02-02 Kali-Chemie Pharma Gmbh Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof
US4460372A (en) * 1981-02-17 1984-07-17 Alza Corporation Percutaneous absorption enhancer dispenser for use in coadministering drug and percutaneous absorption enhancer
US4573996A (en) * 1984-01-03 1986-03-04 Jonergin, Inc. Device for the administration of an active agent to the skin or mucosa
US4624665A (en) * 1984-10-01 1986-11-25 Biotek, Inc. Method of transdermal drug delivery
SE8602666D0 (sv) * 1986-06-16 1986-06-16 Leo Ab Intravaginal devices
US5188835A (en) * 1986-06-16 1993-02-23 Kabi Pharmacia Ab Intravaginal devices
US5223261A (en) * 1988-02-26 1993-06-29 Riker Laboratories, Inc. Transdermal estradiol delivery system
US5340586A (en) * 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
JP2960832B2 (ja) * 1992-05-08 1999-10-12 ペルマテック テクノロジー アクチェンゲゼルシャフト エストラジオールの投与システム
US5460820B1 (en) * 1993-08-03 1999-08-03 Theratech Inc Method for providing testosterone and optionally estrogen replacement therapy to women
US5891868A (en) * 1997-11-21 1999-04-06 Kaiser Foundation Health Plan, Inc. Methods for treating postmenopausal women using ultra-low doses of estrogen

Also Published As

Publication number Publication date
AU760108B2 (en) 2003-05-08
IS5468A (is) 2000-04-26
PL193897B1 (pl) 2007-03-30
EA200000563A1 (ru) 2001-08-27
NO326929B1 (no) 2009-03-16
CA2306881C (en) 2008-09-02
WO1999026631A1 (en) 1999-06-03
NO20002587D0 (no) 2000-05-19
EP1570848A1 (en) 2005-09-07
EP1570848B1 (en) 2008-01-16
NZ504668A (en) 2002-11-26
CN1279611A (zh) 2001-01-10
IL136175A0 (en) 2001-05-20
NO20002587L (no) 2000-07-19
CA2306881A1 (en) 1999-06-03
CN100398110C (zh) 2008-07-02
HUP0004339A2 (hu) 2001-05-28
DE69839026D1 (de) 2008-03-06
IL136175A (en) 2005-11-20
ATE383862T1 (de) 2008-02-15
BR9814984A (pt) 2000-10-03
DE69829501T2 (de) 2006-01-26
AU1591499A (en) 1999-06-15
CZ299226B6 (cs) 2008-05-21
ES2299912T3 (es) 2008-06-01
PL341112A1 (en) 2001-03-26
EP1032398A1 (en) 2000-09-06
DE69829501D1 (de) 2005-04-28
HUP0004339A3 (en) 2001-09-28
ES2241188T3 (es) 2005-10-16
CL2004001852A1 (es) 2005-06-03
SK284971B6 (sk) 2006-03-02
CZ20001602A3 (cs) 2001-02-14
JP2004083599A (ja) 2004-03-18
SK7332000A3 (en) 2001-03-12
IS2132B (is) 2006-08-15
DE69839026T2 (de) 2009-01-08
US5891868A (en) 1999-04-06
JP2001523722A (ja) 2001-11-27
EE200000307A (et) 2001-10-15
KR20010032257A (ko) 2001-04-16
ATE291430T1 (de) 2005-04-15
TR200001460T2 (tr) 2000-11-21
EP1032398B1 (en) 2005-03-23
EA004573B1 (ru) 2004-06-24
EE04221B1 (et) 2004-02-16
PT1032398E (pt) 2005-08-31
KR100576568B1 (ko) 2006-05-08

Similar Documents

Publication Publication Date Title
HK1082919A1 (en) Transdermal treatment of postmenopausal women using ultra-low doses of estrogen
GR3033492T3 (en) Parathyroid hormone and raloxifene for increasing bone mass.
EP0961613A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF BONE RESORPTION DISORDERS, INCLUDING OSTEOPOROSIS
MXPA03005742A (es) Combinacion de un estrogeno y un androgeno para tratar deficiencias hormonales en mujeres que sufren terapia de reemplazo de estrogenos.
ITMI951160A0 (it) Chiodo endomidollare bloccato adatto in particolare per le fratture del femore
EP1005267A4 (en) METHOD OF TREATING PATHOGENS BASED ON PHOTOTHERAPY AND COMPOSITION USEFUL IN THIS METHOD
EP0987998A4 (en) DECELLULARIZATION OF A FABRIC
DE59812897D1 (de) Vorrichtung zum behandeln von malignen, tumorösen gewebebereichen
MX9703944A (es) Metodo para usar derivados de triaril-etileno en el tratamiento y prevencion de osteoporosis.
IL115224A0 (en) Preparations for use in the treatment of osteoporosis
AU7490696A (en) Apparatus for treating ankle fractures
ZA973381B (en) Process and apparatus for treating leather.
MD1270G2 (ro) Metodă de tratament al pseudoartrozei de scafoid carpian
EP0646651A3 (en) Method for improving the treatment of leather.
AU1275400A (en) Method and apparatus for treating contaminated waste
PL311342A1 (en) Stabilising, compressing and dynamising device for plaster-free treating bone fractures
PL329592A1 (en) Anhydrous method of treating textiles and treatment bed therefor
HU9402560D0 (en) Healing treatment for men and women
PL107566U1 (en) Rehabilitation bank for treating platypodia and heel valgity
UA31670A (uk) Спосіб лікування синдрому після тотальної оваріектомії у жінок пери- та постменопаузального віку
UA30394A (uk) Спосіб комплексного лікування переломів нижньої щелепи
IT1276508B1 (it) Plantare ortopedico a stimolazione variabile.
UA36341A (uk) Спосіб лікування запальних процесів навколозубних тканин

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20151119